CN117357462B - Composition for inhibiting lipofuscin and preparation method and application thereof - Google Patents
Composition for inhibiting lipofuscin and preparation method and application thereof Download PDFInfo
- Publication number
- CN117357462B CN117357462B CN202311675228.6A CN202311675228A CN117357462B CN 117357462 B CN117357462 B CN 117357462B CN 202311675228 A CN202311675228 A CN 202311675228A CN 117357462 B CN117357462 B CN 117357462B
- Authority
- CN
- China
- Prior art keywords
- lipofuscin
- parts
- extract
- inhibiting composition
- citrus peel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 241000186660 Lactobacillus Species 0.000 claims abstract description 24
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 24
- 241000207199 Citrus Species 0.000 claims abstract description 23
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 23
- 238000000855 fermentation Methods 0.000 claims abstract description 19
- 230000004151 fermentation Effects 0.000 claims abstract description 19
- 229920000669 heparin Polymers 0.000 claims abstract description 17
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 17
- 229960001008 heparin sodium Drugs 0.000 claims abstract description 17
- 241000911175 Citharexylum caudatum Species 0.000 claims abstract description 14
- 239000000177 juniperus communis l. berry Substances 0.000 claims abstract description 14
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 12
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 12
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims description 37
- 239000000047 product Substances 0.000 claims description 20
- 239000002537 cosmetic Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 5
- 108010087806 Carnosine Proteins 0.000 claims description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 5
- 229940044199 carnosine Drugs 0.000 claims description 5
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 239000011550 stock solution Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 208000003251 Pruritus Diseases 0.000 abstract description 7
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 5
- 208000003455 anaphylaxis Diseases 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 208000010201 Exanthema Diseases 0.000 abstract description 4
- 201000005884 exanthem Diseases 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 4
- 206010037844 rash Diseases 0.000 abstract description 4
- 238000013329 compounding Methods 0.000 abstract description 3
- 239000002932 luster Substances 0.000 abstract description 2
- 230000037394 skin elasticity Effects 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000003756 stirring Methods 0.000 description 22
- 230000001815 facial effect Effects 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 239000008223 sterile water Substances 0.000 description 12
- 229920001661 Chitosan Polymers 0.000 description 11
- 241000219138 Luffa Species 0.000 description 11
- 235000003956 Luffa Nutrition 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 239000002994 raw material Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 230000032683 aging Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000000887 face Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a lipofuscin-inhibiting composition, and a preparation method and application thereof, wherein the lipofuscin-inhibiting composition comprises the following components in parts by weight: 0.1-3 parts of juniper berry extract, 0.1-2 parts of citrus peel extract, 0.1-5 parts of lactobacillus fermentation product extract and 0.01-5 parts of plantain seed extract; the inhibition effect on lipofuscin is obvious by compounding the juniper berry extract, the citrus peel extract, the lactobacillus fermentation product extract and the plantain seed extract in a specific proportion, and the problems of anaphylactic reaction such as rash, itching and the like of human skin are improved by assisting with heparin sodium. The invention realizes the effect of inhibiting lipofuscin from multiple layers and multiple ways through scientific collocation of the components, so that the skin is healthy, transparent and fine, and the skin elasticity and luster are maintained.
Description
Technical Field
The invention belongs to the field of daily chemicals, and particularly relates to a composition for inhibiting lipofuscin, and a preparation method and application thereof.
Background
Lipofuscin, also known as age pigment or senile plaque, is a substance that is brown yellow, dense in electrons and autofluorescent, and gradually accumulates in cells after mitosis with age, causing senile diseases such as Alzheimer's disease and atherosclerosis. Lipofuscin accumulation increases with age, and is one of the important indicators of aging, commonly known as "senile plaques". Lipofuscin cannot be degraded nor cleared by exocytosis, and thus accumulates in lysosomes and cytoplasm of long-lived cells of animals after mitosis and aging.
Lipofuscin is deposited in cells of various organs of human body, resulting in slow cell metabolism and reduced activity, thereby causing deterioration of human organ function and aging. The anti-aging enzyme GSH-PX is synthesized by human cells, and has the main effects of scavenging free radicals, but the synthesis capacity and activity of the anti-aging enzyme are reduced along with the increase of the age, so that the anti-aging factor is gradually increased, the content and activity of the anti-aging enzyme are reduced, and the aging is generated. Wherein lipofuscin is deposited in skin cells to make skin rough, dull, matt, and wrinkle, mottle, etc. The inhibition effect of the existing substances on lipofuscin is not obvious.
Disclosure of Invention
In view of the above-described drawbacks of the prior art, an object of the present invention is to provide a lipofuscin-inhibiting composition. The inhibition effect on lipofuscin is obvious by compounding the juniper berry extract, the citrus peel extract, the lactobacillus fermentation product extract and the plantain seed extract in a specific proportion, and the problems of anaphylactic reaction such as rash, itching and the like of human skin are improved by assisting with heparin sodium. The invention realizes the effect of inhibiting lipofuscin from multiple layers and multiple ways through scientific collocation of the components, so that the skin is healthy, transparent and fine, and the skin elasticity and luster are maintained.
The invention aims to provide a lipofuscin inhibiting composition which comprises the following components in parts by weight: 0.1-3 parts of juniper berry extract, 0.1-2 parts of citrus peel extract, 0.1-5 parts of lactobacillus fermentation product extract and 0.01-5 parts of plantain seed extract.
Preferably, the lipofuscin-inhibiting composition comprises the following components in parts by weight: 0.5-2 parts of juniper berry extract, 0.5-1.5 parts of citrus peel extract, 0.5-4 parts of lactobacillus fermentation product extract and 0.1-4 parts of plantain seed extract.
More preferably, the lipofuscin-inhibiting composition comprises the following components in parts by weight: 1.5 parts of juniper berry extract, 1 part of citrus peel extract, 2 parts of lactobacillus fermentation product extract and 2.5 parts of plantain seed extract.
Preferably, the lipofuscin-inhibiting composition further comprises the following components in parts by weight: heparin sodium 0.001-0.1 parts.
Heparin sodium is an acidic mucopolysaccharide substance, and is added into cosmetics such as nourishing cream, eye cream, acne removing product and hair tonic, and can promote local blood circulation for eyes and face, and promote absorption of other nutrients, but heparin sodium has certain irritation to skin, and some consumers can feel rare skin irritation such as burning sensation or anaphylaxis such as rash and pruritus when using cosmetics containing heparin sodium. In experiments, the inventor finds that the problems of anaphylactic reaction such as rash, pruritus and the like of human skin caused by adding heparin sodium can be solved by compounding the juniper berry extract, the citrus peel extract, the lactobacillus fermentation product extract and the plantain seed extract in a specific proportion.
More preferably, the lipofuscin-inhibiting composition further comprises the following components in parts by weight: heparin sodium 0.005-0.05 parts.
More preferably, the lipofuscin-inhibiting composition further comprises the following components in parts by weight: heparin sodium 0.01 part.
Preferably, the lipofuscin-inhibiting composition further comprises the following components in parts by weight: carnosine 0.001-0.5 parts.
More preferably, the lipofuscin-inhibiting composition further comprises the following components in parts by weight: 0.01-0.1 part of carnosine.
More preferably, the lipofuscin-inhibiting composition further comprises the following components in parts by weight: carnosine 0.05 parts.
Preferably, the extraction process of the citrus peel extract comprises the following steps:
extracting dried and pulverized pericarpium Citri Tangerinae with solvent under heating and ultrasonic, centrifuging, and concentrating supernatant to obtain pericarpium Citri Tangerinae extract.
Preferably, the solvent comprises at least one of ethanol, methanol, water.
More preferably, the solvent is selected from ethanol.
Preferably, the mass ratio of the citrus peel to the solvent is 1: 40-50.
More preferably, the mass ratio of the citrus peel to the solvent is 1:45.
preferably, the heating temperature is 40-50 ℃.
More preferably, the temperature of the heating is 45 ℃.
Preferably, the power of the ultrasonic wave is 300-350W, and the ultrasonic wave time is 15-25 min.
More preferably, the power of the ultrasonic wave is 330W, and the time of the ultrasonic wave is 20min.
Preferably, the extraction process of the lactobacillus fermentation product extract is as follows:
inoculating lactobacillus into culture medium for culturing, sterilizing, and separating solid from liquid to obtain lactobacillus fermentation product extract.
Preferably, the lactic acid bacteria are selected from the group consisting of lactobacillus plantarum.
Preferably, the concentration of the bacterial liquid of the lactobacillus is 10 6 ~10 8 CFU/mL。
More preferably, the concentration of the bacterial liquid of the lactic acid bacteria is 10 7 CFU/mL。
Preferably, the medium is selected from MRS medium.
Preferably, the inoculation amount of the lactobacillus is 0.2-1% of the volume of the culture medium.
More preferably, the lactobacillus is inoculated in an amount of 0.6% by volume of the medium.
Preferably, the temperature of the culture is 25-35 ℃, and the culture time is 8-16 h.
More preferably, the temperature of the cultivation is 30℃and the time of cultivation is 12 hours.
It is still another object of the present invention to provide a cosmetic, wherein the lipofuscin-inhibiting composition is formulated into a cosmetic by adding cosmetically acceptable adjuvants.
Preferably, the cosmetic is selected from any one of facial mask liquid, essence, toner, face cleansing emulsion, stock solution, perfume, foundation solution, cleansing water, foundation cream, concealer, lipstick, rouge, eye shadow or blush.
Preferably, the lipofuscin-inhibiting composition is used in an amount of 0.5-5% by mass of the cosmetic.
More preferably, the lipofuscin-inhibiting composition is used in an amount of 2% by mass of the cosmetic.
Detailed Description
In order to make the technical solution of the present invention better understood by those skilled in the art, the technical solution of the present invention will be clearly and completely described in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present invention without making any inventive effort, shall fall within the scope of the present invention.
The juniper berry extract was purchased from the company Shanghai trade (Shanghai); semen plantaginis extract was purchased from western Ansnot Biotechnology Co., ltd; MRS medium was purchased from Qingdao sea Bo biotechnology Co.
Example 1: extracting citrus peel extract.
15kg of dried citrus peel crushed by a traditional Chinese medicine crusher is sieved by a 80-100 mesh sieve, 450kg of ethanol is added into 10kg of crushed citrus peel, heating is carried out at 45 ℃ and ultrasonic power is carried out for 20min, centrifugation is carried out, and supernatant fluid is concentrated, thus obtaining the citrus peel extract.
Example 2: extraction of lactobacillus fermentation product extract.
The concentration of the bacterial liquid is 10 7 Inoculating Lactobacillus plantarum (Lactobacillus Plantarum) of CFU/mL into MRS culture medium for culturing with an inoculum size of 0.6% of the volume of the culture medium, culturing at 30deg.C for 12 hr, sterilizing at 115deg.C for 20min, centrifuging, collecting supernatant, and concentrating to obtain lactobacillus fermentation product extract.
Example 3: and (3) preparing mask liquid.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 21.43% of juniper berry extract, 14.29% of citrus peel extract, 28.57% of lactobacillus fermentation product extract and 35.71% of plantain seed extract.
Example 4: and (3) preparing mask liquid.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 21.40% of juniper berry extract, 14.27% of citrus peel extract, 28.53% of lactobacillus fermentation product extract, 35.66% of plantain seed extract and 0.14% of heparin sodium.
Example 5: and (3) preparing mask liquid.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 21.25% of juniper berry extract, 14.16% of citrus peel extract, 28.33% of lactobacillus fermentation product extract, 35.41% of plantain seed extract, 0.14% of heparin sodium and 0.71% of carnosine.
Comparative example 1: and (3) preparing mask liquid.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 100% of juniper berry extract.
Comparative example 2: and (3) preparing mask liquid.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 100% of citrus peel extract.
Comparative example 3: and (3) preparing mask liquid.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 100% of lactobacillus fermentation product extract.
Comparative example 4: and (3) preparing mask liquid.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 100% of plantain seed extract.
Comparative example 5: the facial mask liquid is prepared.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 99.86% of juniper berry extract and 0.14% of heparin sodium.
Comparative example 6: the facial mask liquid is prepared.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 99.86% of citrus peel extract and 0.14% of heparin sodium.
Comparative example 7: the facial mask liquid is prepared.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 99.86% of lactobacillus fermentation product extract and 0.14% of heparin sodium.
Comparative example 8: the facial mask liquid is prepared.
Mixing glycerol 8% and sterile water 86%, stirring, adding water-soluble chitosan 2%, lipofuscin inhibiting composition 2% and luffa water 2%, and stirring to obtain facial mask liquid;
the lipofuscin inhibiting composition is prepared from the following raw materials in percentage by mass: 99.86% of semen plantaginis extract and 0.14% of heparin sodium.
Test example 1: testing for inhibition of lipofuscin.
1mg/mL BSA (bovine serum albumin) was mixed with 2mmol/L MDA (malondialdehyde) in 0.1mol/L PBS, pH7.4, and incubated in an incubator at 37℃for 72 hours, respectively, to form a lipofuscin system. The system was scanned by a fluorescence spectrophotometer (slit width was set to 2.5 nm), and the fluorescence intensity was measured at an excitation wavelength of 395nm and an emission wavelength of 460 nm.
The mask solutions of example 3 and comparative examples 1 to 4, which were dissolved in sterile water at 4g/L, were added to the lipofuscin system, respectively, and incubated for 72 hours in a constant temperature incubator at 37 ℃. The system was scanned by a fluorescence spectrophotometer (slit width was set to 2.5 nm), and the fluorescence intensity was measured at an excitation wavelength of 395nm and an emission wavelength of 460 nm.
Fluorescence intensity decrease ratio (%) = (fluorescence intensity before addition of mask liquid-fluorescence intensity after addition of mask liquid)/fluorescence intensity before addition of mask liquid×100%
Table 1. Results of lipofuscin inhibition assay.
As is clear from Table 1, the decrease rate of fluorescence intensity of the mask liquid of example 3 of the present invention was larger than that of the mask liquids of comparative examples 1 to 4, indicating that the mask liquid of example 3 had synergistic lipofuscin-inhibiting effect.
Test example 2: and (5) spot removing test.
Selecting 70 female volunteers with color spots on the faces of 35-55 years old, randomly dividing the female volunteers into 7 groups, and recording the condition of dark skin and color spots on the front face of each volunteer by a dermatologist under the conditions that the ambient humidity is 50+/-10% and the temperature is 23+/-1 ℃ after the volunteers wash the faces on day 0; each group of volunteers used the mask solutions of examples 3 to 5 and comparative examples 1 to 4 to apply the mask at the same dosage of 2mg/cm 2 3 times per week for 30min each time; after 21 days of use, the skin care product is prepared from the same dermatology department medicine under the conditions that the ambient humidity is 50+/-10 percent and the temperature is 23+/-1 DEG CThe condition of the skin darkness and the color spots of the back face of each volunteer using the product is checked, and the use effect scoring is carried out by comparing the photos recorded by photographing on day 0;
facial skin darkness, stain condition scoring criteria:
5 minutes (skin is obviously brightened and the color spots disappear);
4 minutes (skin is obviously brightened and color spots are obviously reduced);
3 minutes (skin is brighter and color spots are less);
score 2 (skin lightening, slightly reduced stain);
score 1 (skin lightening was not evident, stain was essentially unchanged);
the average of the 10 scores was taken as the final result for each group, and the results are shown in table 2.
Table 2. Freckle removal test results.
As can be seen from Table 2, the mask liquid prepared in examples 3 to 5 of the present invention has an obvious freckle removing effect.
Test example 3: and (5) testing anaphylactic reaction.
Selecting 50 female volunteers with healthy skin and no itching of 35-55 years old, randomly dividing into 5 groups of 10 people each, respectively applying the facial mask liquid of the example 4 and the facial mask liquid of the comparative examples 5-8 on the fixed areas on the inner sides of the two arms of the volunteers, wherein the dosage is 2mg/cm 2 The medicine is used once in the morning and evening every day for 30min each time; after 21 days of use, recording skin itch;
table 3. Allergic reaction test results.
As can be seen from Table 3, the mask liquid prepared in example 4 was effective in improving the problems of allergic reactions such as itching, etc. caused by the addition of heparin sodium.
Finally, it should be noted that the above-mentioned embodiments are merely for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the above-mentioned embodiments, it should be understood by those skilled in the art that modifications and equivalents may be made to the specific embodiments of the present invention after reading the present specification, and these modifications and variations do not depart from the scope of the invention as claimed in the pending claims.
Claims (6)
1. The lipofuscin inhibiting composition is characterized by comprising the following components in parts by weight: 0.1-3 parts of juniper berry extract, 0.1-2 parts of citrus peel extract, 0.1-5 parts of lactobacillus fermentation product extract and 0.01-5 parts of plantain seed extract;
the extraction process of the citrus peel extract comprises the following steps:
extracting dried and crushed citrus peel with solvent under heating and ultrasonic, centrifuging, and concentrating supernatant to obtain citrus peel extract;
the solvent is selected from ethanol; the heating temperature is 40-50 ℃; the power of the ultrasonic wave is 300-350W, and the ultrasonic wave time is 15-25 min;
the extraction process of the lactobacillus fermentation product extract is as follows:
inoculating lactobacillus into a culture medium for culture, sterilizing, and performing solid-liquid separation to obtain lactobacillus fermentation product extract;
the temperature of the culture is 25-35 ℃, and the culture time is 8-16 h.
2. The lipofuscin-inhibiting composition of claim 1 further comprising the following components in parts by weight: heparin sodium 0.001-0.1 parts.
3. The lipofuscin-inhibiting composition of claim 2 further comprising the following components in parts by weight: carnosine 0.001-0.5 parts.
4. A cosmetic comprising the lipofuscin-inhibiting composition according to any one of claims 1-3, and a cosmetically acceptable adjuvant.
5. The cosmetic according to claim 4, wherein the cosmetic is selected from any one of a mask lotion, a essence, a toner, a cleanser, a stock solution, a perfume, a foundation solution, a makeup remover, a foundation cream, a concealer, a lipstick, a rouge, an eye shadow, and a blush.
6. The cosmetic according to claim 4, wherein the lipofuscin-inhibiting composition is used in an amount of 0.5-5% by mass of the cosmetic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311675228.6A CN117357462B (en) | 2023-12-08 | 2023-12-08 | Composition for inhibiting lipofuscin and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311675228.6A CN117357462B (en) | 2023-12-08 | 2023-12-08 | Composition for inhibiting lipofuscin and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117357462A CN117357462A (en) | 2024-01-09 |
| CN117357462B true CN117357462B (en) | 2024-02-13 |
Family
ID=89389585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311675228.6A Active CN117357462B (en) | 2023-12-08 | 2023-12-08 | Composition for inhibiting lipofuscin and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117357462B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108785155A (en) * | 2017-04-28 | 2018-11-13 | 捷通国际有限公司 | Composition and correlation technique for treating cutaneous pigmentation |
| CN109700753A (en) * | 2019-02-14 | 2019-05-03 | 成都市葆姿健康管理有限公司 | A kind of skin care compositions and its application and preparation method with moisturizing anti-oxidation efficacy |
| CN110787086A (en) * | 2019-11-26 | 2020-02-14 | 广州市胜梅化妆品有限公司 | Composition for whitening skin and removing freckles and preparation method thereof |
| CN113730314A (en) * | 2021-10-22 | 2021-12-03 | 广州市胜梅化妆品有限公司 | Anti-aging and relieving composition and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3231437B1 (en) * | 2014-12-09 | 2020-02-05 | Nihon Sizen Hakkoh Co., Ltd. | Aging inhibitor |
-
2023
- 2023-12-08 CN CN202311675228.6A patent/CN117357462B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108785155A (en) * | 2017-04-28 | 2018-11-13 | 捷通国际有限公司 | Composition and correlation technique for treating cutaneous pigmentation |
| CN109700753A (en) * | 2019-02-14 | 2019-05-03 | 成都市葆姿健康管理有限公司 | A kind of skin care compositions and its application and preparation method with moisturizing anti-oxidation efficacy |
| CN110787086A (en) * | 2019-11-26 | 2020-02-14 | 广州市胜梅化妆品有限公司 | Composition for whitening skin and removing freckles and preparation method thereof |
| CN113730314A (en) * | 2021-10-22 | 2021-12-03 | 广州市胜梅化妆品有限公司 | Anti-aging and relieving composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117357462A (en) | 2024-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105434323B (en) | Saccharomycetes to make fermentation compound and its application in skin whitening, moisturizing skin care item | |
| CN110249055B (en) | Fermented product and method for producing same | |
| JP2020193198A (en) | Fermented extract of aerial parts of bitter orange | |
| JP2023171950A (en) | Anti-aging agent, antioxidant, anti-inflammatory agent, and whitening agent, as well as cosmetic | |
| CN110022853B (en) | Composition for activating protein L-isoaspartic acid methyltransferase | |
| JP2000044485A (en) | Active oxygen species scavenger and skin cosmetic | |
| KR102094846B1 (en) | Method of mixed crude herb cosmetic composition effective for improving skin and mixed crude herb cosmetic composition thereby | |
| KR20190063549A (en) | Cosmetic Composition Comprising Bamboo Fermented Extract | |
| CN111419760A (en) | Fresh black tiger leaf extracting solution and preparation method and application thereof | |
| KR20100006796A (en) | Anti-aging cosmetic composition comprising herb ferment extract | |
| CN105902812A (en) | Traditional Chinese medicine composition with beauty treatment effect, facial mask cream, and preparation methods of traditional Chinese medicine composition and facial mask cream | |
| CN107970278A (en) | Hydrolysate of wax-apple water extract and preparation method thereof and purposes | |
| CN117357462B (en) | Composition for inhibiting lipofuscin and preparation method and application thereof | |
| CN113384482A (en) | Moisturizing and skin-tendering essence and preparation method thereof | |
| CN116712358A (en) | Compound essential oil for skin and pharmaceutical composition containing same | |
| CN116602894A (en) | Skin care product containing boa oil extract for delaying skin aging and removing wrinkles, and its preparation method | |
| KR101806007B1 (en) | Manufacturing method of cosmetic composition containing nano particle natural materials and cosmetic composition manufactured by the same | |
| CN115414313A (en) | Anti-aging composition containing micrococcus lysate and preparation method thereof | |
| JP3105664B2 (en) | External preparation for skin | |
| KR102139471B1 (en) | Fermented composition of ice plant and collagen for anti-aging and anti-wrinkle, method for preparing the same and cosmetic composition comprising the same | |
| CN113101255A (en) | Anti-premature composition and preparation method and application thereof | |
| TWI648054B (en) | Hydrolysate of water extract of Asparagus officinalis, preparation method and use thereof | |
| JP2002047130A (en) | Melanogenesis promoter | |
| KR20160122379A (en) | Manufacture method of fermented complex using dongchimi materials and cosmetic composition using by the method and cosmetic comprising the cosmetic composition | |
| KR102182927B1 (en) | Cosmetic composition comprising extracts of fermented oenanthe javanica d.c using mycelium of cauliflower mushroom for anti-oxidation, anti-wrinkle, improving skin elasticity and skin whitening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |